Immunome licenses novel antibodies from Nectin

US clinical-stage biotech Immunome (Nasdaq: IMNM) has announced exclusive license agreement with Israel-based Nectin Therapeutics for rights to a panel of antibodies targeting an undisclosed target.

"This agreement allows Nectin to realize value while further pursuing and enabling the focus on our first-in-class anti-PVR program (NTX1088) through its ongoing clinical study in tumor types with high unmet need as well as advance our novel ADCs into clinical development. Immunome's leadership team's track record of developing and commercializing novel ADC therapies makes it an ideal partner to advance these promising assets," said Fabian Tenenbaum, chief executive of Nectin Therapeutics.

"Immunome believes the next generation of transformative antibody drug conjugates will address novel targets by pairing high-quality antibodies with innovative linker-payload technology," said Clay Siegall, president and chief executive of Immunome, adding: "We appreciate the work Nectin has done on these antibodies and look forward to advancing them further."